NovaBridge Biosciences (NBP) officer plans $100K open-market ADS buy

Rhea-AI Filing Summary

NovaBridge Biosciences reports that Dr. Sean Cao, its Chief Business Development Officer and Board member, intends to purchase up to $100,000 of the company’s American depositary shares in open market transactions. These purchases began on January 21, 2026, and there is no guarantee regarding the exact number of ADSs that will be bought or the time period over which they will occur.

The company also reiterates standard forward-looking statement language, highlighting that expectations about potential ADS purchases, its drug candidates, and anticipated clinical milestones involve risks and uncertainties, including market conditions, clinical results, regulatory decisions, intellectual property protection, reliance on third parties, and its need for additional funding.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number: 001-39173

NovaBridge Biosciences

2440 Research Boulevard, Suite 400

Rockville, MD 20850

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒                Form 40-F ☐

Dr. Sean Cao, the Chief Business Development Officer and member of the Board of Directors of NovaBridge Biosciences (the “Company”), intends to purchase up to $100,000 of the Company’s American depositary shares (“ADSs”) in open market transactions. The purchases started on January 21, 2026. The Company cannot guarantee the number of ADSs to be purchased or the time frame in which the ADSs will be bought in the open market.

Forward Looking Statements

This current report on Form 6-K contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “believes”, “designed to”, “anticipates”, “future”, “intends”, “plans”, “potential”, “estimates”, “confident”, and similar terms or the negative thereof. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the potential open market purchases by Fu Wei; the strategy, clinical development, plans, results, safety and efficacy of givastomig and VIS-101 and its other drug candidates; the strategic and clinical development of the Company’s drug candidates, including givastomig, ragistomig, uliledlimab, and VIS-101; anticipated clinical milestones and results, and related timing. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: prevailing market conditions; the Company’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of the Company’s drug candidates; the Company’s ability to achieve commercial success for its drug candidates, if approved; the Company’s ability to obtain and maintain protection of intellectual property for its technology and drugs; the Company’s reliance on third parties to conduct drug development, manufacturing and other services; the Company’s limited operating history and the Company’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and those risks more fully discussed in the “Risk Factors” section in the Company’s annual report on Form 20-F filed with the SEC on April 3, 2025 as well as the discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to the Company. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NovaBridge Biosciences
	By	:	/s/ Xi-Yong Fu
	Name	:	Xi-Yong (Sean) Fu
	Title	:	Chief Executive Officer

Date: January 22, 2026

FAQ

What did NovaBridge Biosciences (NBP) disclose in this Form 6-K?

NovaBridge Biosciences disclosed that Dr. Sean Cao, its Chief Business Development Officer and Board member, intends to purchase up to $100,000 of the company’s American depositary shares in open market transactions, with purchases having started on January 21, 2026.

How many NovaBridge Biosciences (NBP) ADSs will be purchased and over what period?

The company states that Dr. Sean Cao intends to purchase up to $100,000 of ADSs in the open market but notes it cannot guarantee the number of ADSs to be purchased or the time frame over which they will be bought.

Who is planning to buy NovaBridge Biosciences (NBP) ADSs?

Dr. Sean Cao, Chief Business Development Officer and a member of the Board of Directors of NovaBridge Biosciences, is the individual who intends to purchase up to $100,000 of the company’s ADSs in open market transactions.

When did the insider ADS purchases at NovaBridge Biosciences (NBP) begin?

The planned open market purchases of NovaBridge Biosciences ADSs by Dr. Sean Cao began on January 21, 2026, according to the company’s disclosure.

Does NovaBridge Biosciences (NBP) provide any guarantees about the ADS purchase plan?

No. The company explicitly states it cannot guarantee the number of ADSs that will be purchased or the time frame in which they will be bought in the open market.

What risks and uncertainties does NovaBridge Biosciences (NBP) highlight in its forward-looking statements?

The company notes risks including prevailing market conditions, its ability to demonstrate safety and efficacy of its drug candidates, clinical results and regulatory decisions, commercial success if drugs are approved, intellectual property protection, reliance on third parties, limited operating history, and the need for additional funding, as well as risks described in its Form 20-F and subsequent SEC filings.